Novocure LTD Schedule 13G passive stakes

Soleus Capital Master Fund and affiliated entities have reported a 9.1% beneficial ownership stake in Novocure Limited.

Vanguard Portfolio Management has reported a beneficial ownership of 5.57% in Novocure Ltd's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Novocure Ltd, reporting 0% beneficial ownership following an internal corporate realignment.

Soleus Capital Master Fund and related entities have disclosed a 7.6% beneficial ownership stake in NovoCure Limited, totaling 8,530,665 ordinary shares.

Capital World Investors reported a 1.8% beneficial ownership stake in NovoCure Ltd., holding 2 million shares as of September 30, 2025.

Soleus Capital Master Fund and related entities have reported a beneficial ownership of 8.6% in NovoCure Limited, totaling 9,644,872 ordinary shares.

Capital World Investors has disclosed a 5.7% passive ownership stake in NovoCure Ltd., holding over 6.38 million common shares.

Soleus Capital Master Fund and its affiliates have disclosed a 6.2% beneficial ownership stake in NovoCure Limited, holding 6,904,302 ordinary shares.

Capital International Investors has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in NovoCure Ltd.'s common stock as of June 30, 2025.

Investment giant BlackRock, Inc. has reported a passive beneficial ownership of 8.3% in NovoCure Ltd's common stock as of March 31, 2025.

Soleus Capital Master Fund, L.P. and its affiliated entities have reported a passive beneficial ownership of 5.0% in NovoCure Limited, totaling 5,521,414 ordinary shares.